Results 161 to 170 of about 35,703 (223)

Proactive, short-term PCSK9 inhibition after PCI in patients with coronary artery disease at high residual risk: rationale and design of the randomized HANYANG-PICK trial. [PDF]

Front Cardiovasc Med
Kim W, Park S, Shin JH, Kook H, Lim YH.
europepmc   +1 more source

PCSK9 Inhibition

Journal of the American College of Cardiology, 2012
openaire   +1 more source

Transforming growth factor beta reduces proprotein convertase subtilisin/kexin type 9 in the supernatant of hepatic stellate cells. [PDF]

World J Hepatol
Bundschuh J, Neumann M, Zimny S, Spirk M, Buechler C.   +4 more
europepmc   +1 more source

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study. [PDF]

J Int Med Res
Wang Y, Liu X, Huang S.
europepmc   +1 more source

Amgen's PCSK9 patents upheld [PDF]

Nature Biotechnology, 2016
openaire   +2 more sources

PCSK9 in Cancer: Biological Mechanisms and Implications for Therapeutic Resistance. [PDF]

Biomolecules
Azmi NU, Syahdi RR, Puteri MU, Yanuar A, Kato M, Saputri FC.   +5 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat [PDF]

, 2014

core   +1 more source

Advanced therapy in familial hypercholesterolemia. [PDF]

Can Fam Physician
Gao E, Brunham LR, Goldman RD.
europepmc   +1 more source

Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Hamzah KA, Kurmasha YH, Abdrabo MF, Srour MF, Al-Shammari AS, Badi MHI, Shweliya MA, Jena N, Sattar Y.   +8 more
europepmc   +1 more source

Ezetimibe vs Inclisiran in Coronary Artery Disease and Hyperlipidemia: A Propensity-Matched Analysis. [PDF]

JACC Adv
Akbar UA, Ijaz H, Banga A, Cheshire M, Shakeel S, Jena N, Alexander T, Dani SS.   +7 more
europepmc   +1 more source